文献速递生殖医学

滋养外胚层再活检与早期妊娠血清β-HCG水平的关系

Relationship between trophectoderm re-biopsy and serum beta-HCG levels in early pregnancies.
PubMed 文献 · Reprod Biomed Online · 2026-09-12

本回顾性队列研究纳入280例单次冻胚移植后活产患者,按1:3匹配比较再活检、单次活检和未活检组的血清β-HCG。再活检组移植后第9天和第11天β-HCG均显著低于其他两组,但围产期结局相似。再活检后β-HCG较低不一定提示预后不良,需结合语境解读。

要点

  • 再活检组移植后第9天β-HCG显著低于单次活检和未活检组。
  • 再活检组第11天β-HCG及第9至11天增幅也显著更低。
  • 再活检组阳性妊娠、临床妊娠和活产率低于单次活检,但与未活检相似。

核心结论

  • 滋养外胚层再活检与活产早期妊娠中显著较低的血清β-HCG相关,但围产期结局无相应差异。
  • 再活检后冻胚移植的β-HCG水平较低不一定反映预后受损,需结合语境解读。

研究设计与样本

  • 回顾性队列研究,纳入280例单次冻胚移植后活产患者。
  • β-HCG于移植后第9天和第11天测量。
  • 协变量匹配按1:3比例:再活检组40例,单次活检组120例,未活检组120例。
  • 评估妊娠结局时纳入所有移植再活检胚胎的患者并按1:3匹配:再活检组320例,单次活检组960例,未活检组960例。

主要发现

  • 移植后第9天,再活检组平均β-HCG为111.4 ± 69.0 mIU/ml,显著低于单次活检组149.6 ± 70.2 mIU/ml(P=0.011)和未活检组152.5 ± 80.3 mIU/ml(P=0.008)。
  • 移植后第11天,再活检组平均β-HCG为221.2 ± 208.7 mIU/ml,显著低于单次活检组433.6 ± 246.0 mIU/ml和未活检组448.6 ± 230.0 mIU/ml(两者P<0.001)。
  • 第9至11天β-HCG增幅再活检组为98.6%,显著低于单次活检组189.8%(P=0.015)和未活检组194.2%(P=0.008),单次活检与未活检组相似。
  • 再活检组阳性妊娠率65.6%(210/320)低于单次活检组75.7%(727/960)(P<0.001),临床妊娠率55.0%(176/320)低于单次活检组65.1%(625/690)(P=0.002),活产率43.8%(140/320)低于单次活检组53.8%(516/960)(P=0.002),但与未活检组相似。
  • 所有组围产期结局相似。

临床怎么用

  • 再活检后冻胚移植的早期β-HCG水平较低时,不应直接判定预后不良,需结合其他指标综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Is trophectoderm re-biopsy for pre-implantation genetic testing for aneuploidy associated with lower serum beta-HCG (β-HCG) levels in early pregnancies resulting in live births? DESIGN: Retrospective cohort study (n = 280) of patients who underwent single frozen embryo transfer (FET) with a resulting live birth. β-HCG was measured on days 9 and 11 after FET. Covariate-based matching was carried out in a 1:3 ratio: re-biopsy (n = 40); single biopsy (n = 120); and no biopsy (n = 120). To evaluate pregnancy outcomes, all patients who transferred a re-biopsied embryo were included and matched in a 1:3 ratio: re-biopsy (n = 320); single biopsy (n = 960); and no biopsy (n = 960). RESULTS: On day 9 after FET, the re-biopsy group had significantly lower mean β-HCG (111.4 ± 69.0 mIU/ml) compared with the single biopsy (149.6 ± 70.2 mIU/m; P =0.011) and no biopsy (152.5 ± 80.3 mIU/ml, P = 0.008. On day 11 after FET, re-biopsy had significantly lower mean β-HCG (221.2 ± 208.7 mIU/m) compared with single biopsy (433.6 ± 246.0 mIU/ml) and no biopsy (448.6 ± 230.0 mIU/ml) (P < 0.001, both). The percentage increase in β-HCG from day 9 to 11 was significantly lower in re-biopsy (98.6%) compared with single biopsy (189.8%, P = 0.015) and no biopsy (194.2%, P = 0.008), but similar between single biopsy and no biopsy. Perinatal outcomes were similar among all groups. Positive pregnancy test, clinical pregnancy and live birth rates were lower in re-biopsy compared with single biopsy (65.6% [210/320] versus 75.7% [727/960], P < 0.001; 55.0% [176/320] versus 65.1% [625/690], P = 0.002; 43.8% [140/320] versus 53.8% [516/960], P = 0.002, respectively), but similar between re-biopsy and no biopsy. CONCLUSIONS: Trophectoderm re-biopsy was associated with significantly lower β-HCG in early pregnancies resulting in live births without corresponding differences in perinatal outcomes. These findings suggest that β-HCG levels after re-biopsied FET may require contextual interpretation, as lower levels do not necessarily reflect a compromised prognosis.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Zhuo R, Alkon-Meadows T, Estevez SL, et al. Relationship between trophectoderm re-biopsy and serum beta-HCG levels in early pregnancies. Reprod Biomed Online. 2026. PMID: 42874325. doi:10.1016/j.rbmo.2026.105974

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。